ALLMedicine™ Peripheral Neuropathy Center

Aug 13th, 2022 - This study aims to co-design an evidence- and theory-based behavioural intervention to reduce the impact of chemotherapy-induced peripheral neuropathy (CIPN) symptoms on patients' quality of life. Guided by the Medical Research Council Framework f...

Aug 13th, 2022 - To explore the impact of acupuncture with other complementary and integrative medicine (CIM) modalities on chemotherapy-induced peripheral neuropathy (CIPN) and quality of life (QoL) in oncology patients. In this prospective, pragmatic, and patien...

Aug 12th, 2022 - Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus. Epalrestat, an aldose reductase inhibitor, has been approved for clinical therapy for diabetic peripheral neuropathic pain. In the present study, solid lipi...

Aug 9th, 2022 - We explored the impact of persistent sensory and motor taxane-induced peripheral neuropathy (TIPN) symptoms on health-related quality of life (HRQL) among early-stage breast cancer survivors (ESBCS). A population-based cohort of 884 residual-free ...

Aug 7th, 2022 - To assess the safety, dosing, and preventive effects of cannabidiol (CBD) on chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving oxaliplatin- or paclitaxel-based chemotherapy. Patients with cancer scheduled to undergo treatment...

Jul 15th, 2020 - To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. An Expert Panel conducted targeted systematic literature reviews ...

Aug 1st, 2022 - Researchers published the study covered in this summary on researchsquare.com as a preprint that has not yet been peer reviewed. Key Takeaways In Japanese adults with type 1 diabetes insulin-pump treatment (continuous subcutaneous insulin infusion...

May 4th, 2022 - Key Takeaway Medium to high levels of anxiety increase the risk of chemotherapy-induced peripheral neuropathy (CIPN) in women with breast cancer. Why This Matters CIPN is a common side effect of taxane-based chemotherapy and has negative effects o...

Sep 30th, 2021 - NEW YORK (Reuters Health) - Duloxetine should be a first-line treatment for chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors, according to updated guidelines from the American Society of Clinical Oncology (ASCO). "The mo...

Feb 25th, 2021 - NEW YORK (Reuters Health) - Older patients with low hemoglobin and higher body mass index - particularly women - were more likely to experience chemotherapy-induced peripheral neuropathy (CIPN) in a cohort study. "The identification of these risk ...

Feb 15th, 2021 - Prescriptions for opioids as a first-line treatment for painful diabetic peripheral neuropathy (DPN) outnumbered those for other medications between 2014 and 2018, despite the fact that the former is not recommended, new research indicates. "We kn...